[Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine].
Molsidomine is able to restore a better balance between myocardial oxygen supply and demand during myocardial ischaemia, by inducing a prolonged decrease in the left ventricular wall pressure, by reducing the venous return to the heart and by dilating the large coronary trunks. Molsidomine is also able to redistribute the coronary blood towards the deep sub-endocardial layers during a transient or permanent coronary occlusion, by complex changes in the metabolic autoregulation, by dilatation of the transmural coronary arteries and by reduction of the extravascular compression forces. Finally, by inhibiting platelet aggregation and by a possible action thromboxane A2/prostacyclin synthesis, molsidomine exerts a real anti-thrombotic effect which helps reduce ventricular arrhythmia, improve segmental contractility and reduce the size of the post-stenotic infarct.
D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000378:metabolism / Q000503:physiopathology*; D004285:Dogs; D011464:Epoprostenol / Q000096:biosynthesis; D008981:Molsidomine; D010069:Oxadiazoles / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D013558:Sydnones / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000096:biosynthesis
D010069:Oxadiazoles; D013558:Sydnones; D013928:Thromboxane A2; D008981:Molsidomine; D011464:Epoprostenol
Redistribution du débit coronaire, amélioration fonctionnelle du myocarde ischémique et réduction de la taille de l'infarctus expérimental par la molsidomine.